{"denoms":[{"counts":[{"groupId":"BG000","value":"65"}],"units":"Participants"}],"groups":[{"description":"SP-02L (darinaparsin for injection): Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days","id":"BG000","title":"SP-02L (Darinaparsin for Injection)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"28","upperLimit":"85","value":"68.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"45"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"65"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37"}]}],"title":"Japan"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"South Korea"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Taiwan"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Hong Kong"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"43"}],"title":"Peripheral T-cell lymphoma not otherwise specified"},{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Angioimmunoblastic T-cell Lymphoma"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Anaplastic large cell lymphoma, ALK-negative"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Anaplastic large cell lymphoma, ALK-positive"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Histopathological Diagnosis","unitOfMeasure":"Participants"}],"populationDescription":"Safety analysis set included all patients who received at least one dose of SP-02L (darinaparsin for injection)."}